他汀类药物治疗可改善急性冠状动脉综合征患者的血清膜联蛋白A1水平：一项病例对照研究。
Statin therapy improves serum Annexin A1 levels in patients with acute coronary syndrome: A case-controlled study.
作者信息
Al-Kuraishy Hayder M, Al-Gareeb Ali I, Samy Oula Mohamed
机构信息
Department of Pharmacology, Toxicology and Medicine, College of Medicine, Almustansiriya University, Baghdad, Iraq.
出版信息
Int J Crit Illn Inj Sci. 2021 Jan-Mar;11(1):4-8. doi: 10.4103/IJCIIS.IJCIIS_49_20. Epub 2021 Mar 27.
BACKGROUND
The objective of the study is to estimate the protective role of statins in patients with acute coronary syndrome (ACS) through modulation of annexin A1 (AnxA1) serum levels.
METHODS
A total number of 63 patients with ACS were recruited compared with 25 healthy control subjects. The enrolments were divided into - Group (A): Patients with ACS on atorvastatin ( = 20), Group (B): Patients with ACS on rosuvastatin ( = 20), Group (C): Patients with ACS but not on statin therapy ( = 23), and Group (D): Healthy controls ( = 25). Body mass index and both systolic blood pressure and diastolic blood pressures were measured. Lipid profile, atherogenic index, cardiac risk ratio, cardiovascular risk index, and human AnxA1 level were estimated.
RESULTS
AnxA1 serum level was higher in patients with ACS (3.35 ± 0.84) compared with healthy controls (1.71 ± 0.91) and nonstatin using patients (1.47 ± 0.76) ( = 0.005).
CONCLUSION
AnxA1 serum level is reduced in patients with ACS compared with healthy controls. Patients with ACS on statins therapy showed a higher level of AnxA1 compared with patients with ACS but not on statin therapy.
背景
本研究的目的是通过调节膜联蛋白A1（AnxA1）血清水平来评估他汀类药物在急性冠状动脉综合征（ACS）患者中的保护作用。
方法
共招募了63例ACS患者，并与25名健康对照者进行比较。将入选者分为：A组：接受阿托伐他汀治疗的ACS患者（n = 20）；B组：接受瑞舒伐他汀治疗的ACS患者（n = 20）；C组：患有ACS但未接受他汀类药物治疗的患者（n = 23）；D组：健康对照者（n = 25）。测量体重指数、收缩压和舒张压。评估血脂谱、致动脉粥样硬化指数、心脏风险比、心血管风险指数和人AnxA1水平。
结果
与健康对照者（1.71±0.91）和未使用他汀类药物的患者（1.47±0.76）相比，ACS患者的AnxA1血清水平更高（3.35±0.84）（P = 0.005）。
结论
与健康对照者相比，ACS患者的AnxA1血清水平降低。接受他汀类药物治疗的ACS患者与未接受他汀类药物治疗的ACS患者相比，AnxA1水平更高。
Zotero 插件